PriceTargets.com logo

Incyte - INCY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $73.83
  • Forecasted Upside: 9.40%
  • Number of Analysts: 20
  • Breakdown:
  • 1 Sell Ratings
  • 11 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$67.49 As of 10/4/2024 01:00 AM ET
▲ +0.45 (0.67%)

This chart shows the closing price for INCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Incyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

Analyst Price Target is $73.83
▲ +9.40% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $73.83, with a high forecast of $93.00 and a low forecast of $48.00. The average price target represents a 9.40% upside from the last price of $67.49.

This chart shows the closing price for INCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 20 polled investment analysts is to hold stock in Incyte. This rating has held steady since February 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
4/14/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
7/13/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
10/11/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
1/9/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
7/7/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 1 sell ratings
Ratings as of
10/5/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/1/2024Wolfe ResearchInitiated CoverageOutperform$84.00
9/18/2024Truist FinancialReiterated RatingBuy ➝ Hold$83.00 ➝ $74.00
9/17/2024JMP SecuritiesReiterated RatingMarket Perform
9/16/2024GuggenheimBoost TargetBuy ➝ Buy$86.00 ➝ $92.00
9/16/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$66.00 ➝ $68.00
9/16/2024Cantor FitzgeraldReiterated RatingNeutral
9/9/2024William BlairReiterated RatingOutperform
9/9/2024Cantor FitzgeraldReiterated RatingNeutral
9/3/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$67.00 ➝ $67.00
8/15/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$66.00 ➝ $67.00
8/1/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$55.00 ➝ $60.00
7/31/2024CitigroupBoost TargetBuy ➝ Buy$80.00 ➝ $88.00
7/31/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$59.00 ➝ $61.00
7/31/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$61.00 ➝ $66.00
7/31/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$62.00 ➝ $66.00
7/26/2024OppenheimerLower TargetOutperform ➝ Outperform$84.00 ➝ $81.00
7/2/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Underperform$52.00 ➝ $48.00
6/18/2024Cantor FitzgeraldReiterated RatingNeutral
5/23/2024Deutsche Bank AktiengesellschaftInitiated CoverageHold$55.00
5/1/2024TD CowenLower TargetBuy ➝ Buy$88.00 ➝ $80.00
5/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$84.00 ➝ $83.00
5/1/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$56.00 ➝ $52.00
4/24/2024OppenheimerLower TargetOutperform ➝ Outperform$92.00 ➝ $84.00
4/23/2024Cantor FitzgeraldInitiated CoverageNeutral
3/25/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$65.00
3/13/2024Bank of AmericaLower TargetNeutral ➝ Neutral$69.00 ➝ $67.00
2/23/2024Jefferies Financial GroupInitiated CoverageBuy$81.00
2/14/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$58.00 ➝ $64.00
2/14/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$63.00 ➝ $65.00
2/14/2024CitigroupLower TargetBuy ➝ Buy$82.00 ➝ $81.00
2/14/2024Stifel NicolausBoost TargetHold ➝ Hold$67.00 ➝ $68.00
2/14/2024Truist FinancialLower TargetBuy ➝ Buy$91.00 ➝ $84.00
2/14/2024JMP SecuritiesDowngradeOutperform ➝ Market Perform
2/6/2024William BlairReiterated RatingOutperform
12/14/2023MizuhoLower TargetNeutral ➝ Neutral$82.00 ➝ $77.00
12/13/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$93.00
12/13/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$78.00
12/4/2023GuggenheimUpgradeNeutral ➝ Buy$86.00
11/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$91.00
11/21/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$98.00 ➝ $65.00
11/2/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$114.00 ➝ $98.00
11/1/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$74.00 ➝ $63.00
11/1/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$74.00 ➝ $64.00
9/21/2023Truist FinancialReiterated RatingBuy ➝ Buy$91.00
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$92.00
8/2/2023BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$70.00 ➝ $68.00
8/2/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$93.00
8/2/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$74.00
8/2/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$70.00 ➝ $73.00
8/2/2023Stifel NicolausBoost TargetHold ➝ Hold$73.00 ➝ $76.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$100.00 ➝ $91.00
7/25/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$93.00
7/25/2023CitigroupInitiated CoverageBuy$82.00
7/20/2023Morgan StanleyReiterated RatingUnderweight ➝ Underweight$74.00
5/4/2023JMP SecuritiesLower Target$113.00 ➝ $93.00
5/4/2023Bank of AmericaDowngradeBuy ➝ Neutral$84.00
5/3/2023VNET GroupReiterated RatingMaintains
5/3/2023BMO Capital MarketsLower Target$75.00 ➝ $70.00
5/3/2023Royal Bank of CanadaLower Target$79.00 ➝ $70.00
5/3/2023Stifel NicolausLower Target$80.00 ➝ $73.00
5/3/2023MizuhoLower Target$95.00 ➝ $82.00
4/19/2023JMP SecuritiesReiterated RatingMarket Outperform$113.00
4/12/2023Morgan StanleyBoost TargetEqual Weight$76.00 ➝ $77.00
4/10/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$81.00 ➝ $79.00
3/28/2023JMP SecuritiesReiterated RatingMarket Outperform$113.00
3/24/2023SVB SecuritiesUpgradeUnderperform ➝ Market Perform$61.00
3/20/2023William BlairReiterated RatingOutperform
3/7/2023JMP SecuritiesReiterated RatingBuy$113.00
2/16/2023Credit Suisse GroupBoost TargetBuy$95.00 ➝ $100.00
2/13/2023JMP SecuritiesReiterated RatingMarket Outperform$113.00
2/8/2023Piper SandlerReiterated RatingOverweight$100.00
2/8/2023MizuhoReiterated RatingNeutral$95.00
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$82.00 ➝ $80.00
2/8/2023Leerink PartnersReiterated RatingUnderperform$63.00
2/8/2023CowenBoost TargetOutperform$95.00 ➝ $100.00
1/31/2023Piper SandlerInitiated CoverageOverweight$100.00
1/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$72.00 ➝ $75.00
11/2/2022Morgan StanleyBoost TargetEqual Weight$76.00 ➝ $77.00
11/2/2022Royal Bank of CanadaBoost TargetOutperform$77.00 ➝ $82.00
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$86.00 ➝ $80.00
10/18/2022Wells Fargo & CompanyLower TargetEqual Weight$76.00 ➝ $75.00
9/22/2022Evercore ISIDowngradeIn-Line
8/9/2022GuggenheimDowngradeNeutral
8/3/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $76.00
8/3/2022Evercore ISIDowngradeOutperform ➝ Inline$90.00 ➝ $78.00
8/3/2022OppenheimerLower Target$109.00 ➝ $98.00
8/3/2022GuggenheimDowngradeBuy ➝ Neutral
7/28/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$76.00
7/20/2022Leerink PartnersBoost TargetUnderperform$58.00 ➝ $63.00
5/3/2022Stifel NicolausBoost Target$75.00 ➝ $77.00
4/20/2022Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $76.00
2/9/2022Leerink PartnersDowngradeMarket Perform ➝ Underperform$60.00 ➝ $56.00
2/2/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $76.00
1/18/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$78.00 ➝ $90.00
1/3/2022GuggenheimLower Target$118.00 ➝ $104.00
12/17/2021JMP SecuritiesReiterated RatingBuy$108.00
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$75.00
11/4/2021JMP SecuritiesLower TargetMarket Outperform$124.00 ➝ $108.00
11/3/2021OppenheimerLower TargetOutperform$110.00 ➝ $109.00
10/15/2021Cantor FitzgeraldLower TargetNeutral$104.00 ➝ $79.00
10/4/2021Truist FinancialLower TargetBuy$120.00 ➝ $95.00
9/24/2021JMP SecuritiesReiterated RatingBuy$124.00
9/23/2021Morgan StanleyLower TargetEqual Weight$85.00 ➝ $80.00
9/23/2021Royal Bank of CanadaLower TargetSector Perform$91.00 ➝ $86.00
8/4/2021Leerink PartnersLower TargetUnderperform$70.00 ➝ $67.00
7/20/2021BenchmarkUpgradeHold ➝ Buy$89.00
6/25/2021Royal Bank of CanadaLower TargetSector Perform$92.00 ➝ $88.00
6/15/2021William BlairReiterated RatingOutperform
6/15/2021Leerink PartnersReiterated RatingSell
5/5/2021Morgan StanleyLower TargetEqual Weight$86.00 ➝ $85.00
4/5/2021Morgan StanleyLower TargetEqual Weight$93.00 ➝ $86.00
2/10/2021Morgan StanleyLower TargetEqual Weight$97.00 ➝ $93.00
2/10/2021Leerink PartnersDowngradeMarket Perform ➝ Underperform$89.00 ➝ $70.00
1/7/2021Truist FinancialInitiated CoverageBuy$120.00
1/4/2021GuggenheimUpgradeNeutral ➝ Buy
11/9/2020Morgan StanleyLower TargetEqual Weight$103.00 ➝ $97.00
11/6/2020BMO Capital MarketsLower TargetMarket Perform$94.00 ➝ $87.00
11/6/2020Royal Bank of CanadaLower TargetSector Perform$96.00 ➝ $86.00
10/15/2020Bank of AmericaLower TargetBuy$113.00 ➝ $110.00
10/13/2020Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $103.00
8/9/2020CowenReiterated RatingBuy
8/6/2020BMO Capital MarketsBoost TargetMarket Perform$90.00 ➝ $94.00
8/6/2020Credit Suisse GroupLower TargetNeutral$100.00 ➝ $97.00
8/6/2020Morgan StanleyBoost TargetEqual Weight$95.00 ➝ $100.00
8/4/2020MizuhoInitiated CoverageHold$79.00 ➝ $95.00
8/4/2020Leerink PartnersBoost TargetMarket Perform$86.00 ➝ $87.00
8/3/2020Royal Bank of CanadaBoost TargetSector Perform$91.00 ➝ $92.00
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$99.00
7/24/2020William BlairReiterated RatingBuy
7/20/2020Credit Suisse GroupBoost TargetNeutral$88.00 ➝ $100.00
7/17/2020OppenheimerReiterated RatingBuy$121.00
6/17/2020William BlairReiterated RatingBuy
6/16/2020BenchmarkInitiated CoverageHold
6/15/2020OppenheimerInitiated CoverageBuy$120.00
6/4/2020ArgusBoost TargetBuy$92.00 ➝ $124.00
5/26/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
5/19/2020Cantor FitzgeraldBoost TargetNeutral$83.00 ➝ $100.00
5/12/2020Morgan StanleyBoost TargetEqual Weight$94.00 ➝ $95.00
5/6/2020Credit Suisse GroupReiterated RatingHold$88.00
5/6/2020BMO Capital MarketsBoost TargetMarket Perform$74.00 ➝ $90.00
5/6/2020NomuraReiterated RatingBuy$116.00
5/6/2020OppenheimerBoost TargetOutperform$112.00 ➝ $120.00
5/6/2020Royal Bank of CanadaBoost TargetIn-Line ➝ Sector Perform$81.00 ➝ $91.00
5/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$89.00 ➝ $99.00
4/29/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$94.00
4/21/2020OppenheimerBoost TargetOutperform$90.00 ➝ $112.00
4/20/2020Piper SandlerBoost TargetOverweight$95.00 ➝ $110.00
4/19/2020MizuhoReiterated RatingHold$79.00
4/9/2020William BlairReiterated RatingBuy
4/8/2020Royal Bank of CanadaReiterated RatingHold$81.00
4/8/2020Nomura SecuritiesReiterated RatingBuy$116.00
4/7/2020OppenheimerBoost TargetOutperform$85.00 ➝ $90.00
4/6/2020Piper SandlerReiterated RatingBuy
4/1/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00 ➝ $90.00
3/25/2020OppenheimerLower Target$99.00 ➝ $85.00
3/24/2020William BlairInitiated CoverageOutperform
3/18/2020Royal Bank of CanadaReiterated RatingHold$81.00
3/13/2020Bank of AmericaUpgradeNeutral ➝ Buy$83.00
3/11/2020Credit Suisse GroupLower TargetNeutral$86.00 ➝ $81.00
2/19/2020Piper SandlerReiterated RatingBuy
2/19/2020Nomura SecuritiesBoost TargetBuy$111.00 ➝ $116.00
2/19/2020CowenReiterated RatingBuy
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$89.00
2/16/2020Evercore ISIReiterated RatingBuy$92.00
2/13/2020MizuhoReiterated RatingHold$79.00
2/4/2020Bank of AmericaReiterated RatingNeutral$82.00
1/30/2020Royal Bank of CanadaReiterated RatingHold$80.00
1/27/2020Evercore ISIReiterated RatingBuy$92.00
1/23/2020Cantor FitzgeraldBoost TargetNeutral$65.00 ➝ $83.00
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuy
1/14/2020JMP SecuritiesReiterated RatingOutperform$121.00
1/13/2020CowenReiterated RatingBuy
1/6/2020Royal Bank of CanadaReiterated RatingHold ➝ Neutral
1/6/2020Morgan StanleyLower TargetEqual Weight$89.00 ➝ $83.00
1/3/2020Royal Bank of CanadaLower Target$80.00
1/3/2020The Goldman Sachs GroupLower TargetBuy$122.00 ➝ $107.00
1/3/2020Credit Suisse GroupLower TargetNeutral$90.00 ➝ $86.00
1/3/2020OppenheimerLower TargetOutperform$100.00 ➝ $96.00
1/3/2020BMO Capital MarketsLower TargetMarket Perform$85.00 ➝ $74.00
1/3/2020CitigroupReiterated RatingOutperform$100.00 ➝ $96.00
1/3/2020JMP SecuritiesLower TargetMarket Outperform$110.00 ➝ $99.00
1/3/2020Cantor FitzgeraldLower TargetNeutral$75.00 ➝ $65.00
1/2/2020MizuhoDowngradeBuy ➝ Neutral$98.00 ➝ $79.00
1/2/2020Piper Sandler CompaniesReiterated RatingBuy$95.00
1/2/2020CowenReiterated RatingBuy
1/2/2020GuggenheimDowngradeBuy ➝ Neutral
12/18/2019MizuhoReiterated RatingBuy$98.00
11/27/2019MizuhoReiterated RatingBuy$98.00
10/29/2019MizuhoReiterated RatingBuy$95.00
(Data available from 10/6/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2024
  • 21 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2024
  • 18 very positive mentions
  • 19 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2024
  • 23 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2024
  • 24 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/8/2024
  • 36 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2024
  • 22 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2024
  • 34 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2024

Current Sentiment

  • 34 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Incyte logo
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $67.49
Low: $66.45
High: $67.56

50 Day Range

MA: $64.33
Low: $60.29
High: $68.59

52 Week Range

Now: $67.49
Low: $50.27
High: $70.36

Volume

1,236,688 shs

Average Volume

2,423,910 shs

Market Capitalization

$15.15 billion

P/E Ratio

20.45

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

The following equities research analysts have issued research reports on Incyte in the last twelve months: Bank of America Co., BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., William Blair, and Wolfe Research.
View the latest analyst ratings for INCY.

What is the current price target for Incyte?

18 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $73.83, suggesting a possible upside of 9.4%. JMP Securities has the highest price target set, predicting INCY will reach $93.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $48.00 for Incyte in the next year.
View the latest price targets for INCY.

What is the current consensus analyst rating for Incyte?

Incyte currently has 1 sell rating, 11 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INCY, but not buy more shares or sell existing shares.
View the latest ratings for INCY.

What other companies compete with Incyte?

Other companies that are similar to Incyte include PPD, PRA Health Sciences, Medpace, Charles River Laboratories International and ICON Public. Learn More about companies similar to Incyte.

How do I contact Incyte's investor relations team?

Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is (302) 498-6700 and its investor relations email address is [email protected]. The official website for Incyte is www.incyte.com. Learn More about contacing Incyte investor relations.